TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06773208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine (AZC)
Description: 75 mg/m2 daily, on days 1-7, given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax 400 mg orally daily on days 1-28
Study: NCT06772246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Participants will receive a single oral dose of 90 mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of 90 mg
Study: NCT05358938

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Blockade, Immune
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Checkpoint Blockade, Immune
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Checkpoint Blockade, Immune
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Checkpoint Blockade, Immune
Description: Participants will receive clinical care following Moffitt standards for the patient's disease type and therapeutic setting.
Study: NCT04585789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-73763989
Description: JNJ-73763989 will be administered subcutaneously once every 4 weeks up to Week 44.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-56136379
Description: JNJ-56136379 tablets will be administered orally once daily up to 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV)
Description: ETV tablet will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil
Description: Tenofovir disoproxil will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir alafenamide (TAF)
Description: TAF will be administered orally once daily up to 48 weeks as NA treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a (Optional)
Description: PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFN-alpha-2a (Optional)
Description: PegIFN-alpha-2a injection will be administered subcutaneously once weekly after Week 40 for either 12 or 24 weeks.
Study: NCT05470010

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness
Description: A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: A psychological behavioral intervention that trains participants in mindfulness techniques, which involves achieving a moment-to-moment non-judgmental awareness of their internal psychosocial-emotional state through meditation and gentle mindful movements.
Study: NCT06773962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB006
Description: IV infusion.
Study: NCT05776069

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VGA039
Description: Single doses of VGA039
Study: NCT06773962

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion.
Study: NCT06770842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (BESREMi®)
Description: Ropeginterferon alfa 2b is administered subcutaneously once every 2 weeks. The dosing will be 250mcg at Week 0, 350mcg at Week 2, 500mcg at Week 4, and 500mcg every 2 weeks thereafter
Study: NCT06772623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Adizutecan
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Adizutecan
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telisotuzumab Adizutecan
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion
Study: NCT05776069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGA039
Description: Single doses of VGA039

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single doses of Placebo
Study: NCT05850936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assigned Interventions: IOP-lowering eye drops
Description: IOP-lowering eye drops Xalacom eyedrops (combination drops, fixed latanoprost with timolol) will be the first choice for treatment.~1. If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added; If the IOP reduction of 10% is then not achieved at 1 month after adding Brinzolamide 1%, Alphagan 0.2% or Alphagan-P 0.15% eye drops will be added.~2. If an individual is allergic to Xalacom or feels uncomfortable, the eye drops will be switched to Azarga eye drops (combination drops, fixed Brinzolamide with Timolol); If the IOP reduction of 10% is then not achieved at 1 month, Brinzolamide 1% will be added.~3. The effect of IOP lowering would be assessed every week after applying each medication until the target IOP was achieved and follow up the schedule time. If an IOP reduction of 10% is then not achieved, the individual will be excluded from the study.
Study: NCT06772623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV Infusion
Study: NCT06772012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Description: * Frequency: LLLT was administered 3 times per week.~* Duration: Each session lasted approximately 15-20 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.(50)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orofacial Physical Therapy
Description: * Frequency: Orofacial physical therapy sessions were conducted 3 times per week.~* Duration: Each session lasted around 30-40 minutes.~* Total Duration: The therapy was provided for a total of 6 weeks.~* Components:~  * Manual Therapy: Included techniques such as joint mobilization, soft tissue manipulation, and muscle stretching.~ * Therapeutic Exercises: Focused on strengthening, coordination, and improving mobility of the masticatory muscles.~ * Postural Training: Addressed poor posture and cervical muscle spasm.(50)
Study: NCT06771466

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Ultrasound-Guided Erector Spinae Plane Block (group E)
Description: The curvilinear ultrasound transducer should be placed in a cephalocaudal orientation over the midline of the back at the desired level. The probe should then slowly be moved laterally until the transverse process is visible. The transverse process requires differentiation from the rib at that level. The transverse process will be more superficial and wider, while the rib will be deeper and thinner. Upon verification of the transverse process, the trapezius muscle, rhomboid major muscle (if performing at T5 level or higher), and erector spinae muscle should be identified superficial to the transverse process. The Tuohy needle should be inserted superior to the ultrasound probe using an in-plane approach in the cephalad to caudal direction.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral Ultrasound-guided Quadratus Lumborum, Lateral approach (group Q)
Description: With the patient positioned in the lateral position, scanning is usually started at the mid-axillary line between the iliac crest and subcostal margin, moving the probe posteriorly until tapering of the three abdominal muscle layers and appearance of fascia transversalis and QL muscle are observed. The fascia transversalis usually appears as a hyperechoic layer, which forms a safe landmark to separate the muscle layers from the peri-nephric fat and the abdominal contents
Study: NCT06635889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: The dose plan is to use 50 ml of 0.25% bupivacaine which corresponds with a total dose of 125mg.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo of 50 ml of Normal Saline
Study: NCT05974254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Electroacupuncture
Study: NCT06082973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated insulin delivery system algorithm with a dual-hormone configuration (insulin and glucagon) for glucose control
Description: Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID dHmG system, and microdoses of glucagon (GlucaGen®) will be subcutaneously administered based on automatic recommendations for hypoglycemia mitigation. The subcutaneous administration of reconstituted glucagon will be conducted using a 0.5 mL insulin syringe with needle, allowing for precise doses as small as 0.01mg/0.01 mL.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated insulin delivery system with a single-hormone configuration (insulin) with rescue carbohydrate recommendations for glucose control
Description: Participants will wear a CSII system with the CGM device. Insulin will be administered through the AID sHC system, along with automatic rescue carbohydrate recommendations for hypoglycemia mitigation. As per the carbohydrate recommendation, participants will received the suggested amount of carbohydrates using an oral glucose gel containing 15g of carbohydrates per unit.
Study: NCT06193681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pedi@ctivity Exercise Mobile Application Exercise Program
Description: The first group of the study received a mobile application (Pedi@ctivity) based exercise program. With the Pedi@ctivity exercise mobile application, the selected exercises and exercise program will be offered personalized to each adolescent for 12 weeks. After 12 weeks, the effectiveness of the Pedi@ctivity mobile application-based exercise program on the evaluation parameters will be investigated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise Group
Description: In the physiotherapist-supervised personalized exercise program, the exercises selected through the Pedi@ctivity exercise mobile application will be applied to adolescents under the supervision of a physiotherapist (2 sessions face-to-face, 1 session online/synchronous).
Study: NCT05480124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS brain stimulation treatment
Description: Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. tACS will be delivered by passing a small electrical current via the tACS electrodes to the scalp to stimulate brain activity during a computerized behavioral task. The effect of active stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation treatment
Description: Participants will wear an EEG cap on the head attached with EEG-recording and tACS electrodes. Sham tACS will be delivered by passing a transient (approximately 12 seconds ) small electrical current via the tACS electrodes during a computerized behavioral task. The effect of sham stimulation on EEG will be measured via EEG-recording electrodes during short rests (between stimulation blocks). The sham stimulation session will last for approximately 60 minutes. After treatment, participants will be asked about the experience and if there are any side effects.
Study: NCT06484062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirtuvivint
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirtuvivint
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cirtuvivint
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT05952557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Camizestrant. Experimental. Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: Tamoxifen. Comparator. Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: Anastrozole. Comparator. Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: Letrozole. Comparator. Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: Exemestane. Comparator. Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abemaciclib
Description: Abemaciclib adjuvant treatment Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib adjuvant treatment Administered orally
Study: NCT06444516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID123300 ocular lubricant
Description: Investigational ocular lubricant
Study: NCT06298227

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management with Paracerol® and IV PCA with Talinat®
Description: In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative analgesia management with Paracerol® and IV PCA with Talinat®
Description: In the postoperative period, 1 g of acetaminophen (Paracerol®) will be administered intravenously to patients every 8 hours. Patients in all groups will have IV patient-controlled analgesia (PCA- CADD-Solis®) containing 10 mcg/ml fentanyl ( Talinat®). 10 mcg bolus without infusion dose, 20-minute lock time will be the protocol. Postoperative patient evaluation will be performed by another anesthesiologist. If the NRS score is ≥ 4, 0.5 mg/kg IV meperidine (Aldolan®) will be administered as a rescue analgesic.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The block will be applied while the patient is in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed longitudinally 4 cm lateral to the T11 transverse process. The erector spinae muscle and the hyperechoic transverse process will be visualized. Using the in-plane technique, the 100 mm block needle (Stimuplex 360®) will be advanced in the cranio-caudal direction and 5 ml of saline will be injected under the erector spinae muscle to confirm the block location. Once the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum plane block
Description: QLB will be performed with the patient in the lateral decubitus position. The convex probe of US ( GE Healthcare®) will be placed at the level of the 12th rib, just above the iliac crest, in the parasagittal oblique plane, at the L1-L2 level. After the quadratus lumborum, erector spinae, and psoas major muscles are visualized, a 100 mm block needle (Stimuplex 360®) will be advanced in-plane anteriorly to QL, and the needle tip will be brought between the QL and PM muscles (Anterior QLB). The location will be confirmed by hydraulic dissection with 5 ml saline injection. After the block location is confirmed, 40 ml of 0.25% bupivacaine (Marcaine®) will be administered.
Study: NCT06262919

Intervention type: DRUG
Intervention: Tafinlar/Mekinist
Description: There is no treatment allocation. Patients administered Tafinlar/Mekinist by prescription that have started before inclusion of the patient into the study will be enrolled.
Study: NCT05610163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Given IV
Study: NCT05249946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FoodStep - a sustainable health-promoting model for food services and early childhood education and care
Description: The investigators create a sustainable food system model that reduces the climate impact of the food system in early childhood education and care. In practice, the investigators i) promote plant-rich recipes, sustainable food purchases and consumption through municipality food services, ii) renew food education, and iii) reduce food waste in early education and care. To ensure the feasibility and long-term commitment, the investigators bring together municipal stakeholders and key actors within the food system and education sectors to co-create the content of a sustainable food system intervention. The randomized controlled intervention will be carried out at 26 daycare centers within four municipalities in Finland. The impact of the changes at a food system level on children's dietary intake and nutritional status, costs of the whole food system, the climate impact of the menus and children's diets as well as food waste in the daycare centers will be examined.
Study: NCT05610163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Long Course Chemoradiotherapy
Description: Receive LCRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long Course Chemoradiotherapy
Description: Receive LCRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: undergo MRI